- Home
- DYAI vs ICU Comparison
DYAI vs ICU Comparison
Compare DYAI & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DYAI | ICU |
|---|---|---|
| Founded | 1979 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.0M | 15.6M |
| IPO Year | 2026 | 2021 |
Fundamental Metrics
Financial Performance| Metric | DYAI | ICU |
|---|---|---|
| Price | $0.44 | $3.48 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 179.7K | 126.9K |
| Earning Date | 11-11-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,090,345.00 | $1,234,000.00 |
| Revenue This Year | $113.16 | $62.07 |
| Revenue Next Year | $94.92 | $46.55 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 814.07 |
| 52 Week Low | $0.34 | $0.22 |
| 52 Week High | $1.60 | $5.38 |
Technical Indicators
Market Signals| Indicator | DYAI | ICU |
|---|---|---|
| Relative Strength Index (RSI) | 39.53 | 53.77 |
| Support Level | $0.34 | $2.83 |
| Resistance Level | $0.50 | $3.68 |
| Average True Range (ATR) | 0.04 | 0.32 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 56.77 | 48.08 |
Price Performance
Historical ComparisonAbout DYAI Dyadic International Inc.
Dyadic International Inc is a biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.